Cerus Corp. (NASDAQ:CERS)‘s stock had its “outperform” rating reissued by equities research analysts at FBR & Co in a research note issued on Wednesday. They presently have a $10.00 price target on the stock. FBR & Co‘s target price would suggest a potential upside of 57.48% from the stock’s previous close.
Several other brokerages have also recently commented on CERS. Robert W. Baird reaffirmed an “outperform” rating and set a $9.00 target price on shares of Cerus Corp. in a report on Wednesday, June 22nd. Zacks Investment Research cut shares of Cerus Corp. from a “hold” rating to a “sell” rating in a report on Tuesday, August 9th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $9.00 target price on shares of Cerus Corp. in a report on Sunday, July 31st. Finally, BTIG Research reaffirmed a “buy” rating and set a $10.00 target price on shares of Cerus Corp. in a report on Monday, June 20th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $9.10.
In related news, CFO Kevin Dennis Green sold 17,150 shares of the stock in a transaction that occurred on Monday, August 22nd. The shares were sold at an average price of $6.80, for a total transaction of $116,620.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/07/cerus-corp-cers-given-outperform-rating-at-fbr-co.html
Cerus Corp. (NASDAQ:CERS) traded up 3.62% during mid-day trading on Wednesday, reaching $6.58. The company’s stock had a trading volume of 343,340 shares. The firm’s market capitalization is $675.83 million. Cerus Corp. has a 52 week low of $4.27 and a 52 week high of $7.64. The firm’s 50 day moving average price is $6.79 and its 200 day moving average price is $6.12.
Cerus Corp. (NASDAQ:CERS) last announced its earnings results on Thursday, August 4th. The company reported ($0.18) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by $0.01. The firm had revenue of $9.25 million for the quarter, compared to the consensus estimate of $8.88 million. During the same quarter in the previous year, the company earned ($0.17) earnings per share. The company’s revenue for the quarter was up 4.8% on a year-over-year basis. On average, analysts anticipate that Cerus Corp. will post ($0.68) EPS for the current fiscal year.
Other hedge funds recently modified their holdings of the company. Primecap Management Co. CA raised its stake in shares of Cerus Corp. by 4.0% in the first quarter. Primecap Management Co. CA now owns 7,800,000 shares of the company’s stock worth $46,254,000 after buying an additional 300,000 shares in the last quarter. BlackRock Fund Advisors raised its stake in shares of Cerus Corp. by 0.7% in the first quarter. BlackRock Fund Advisors now owns 3,730,957 shares of the company’s stock worth $22,125,000 after buying an additional 24,166 shares in the last quarter. BlackRock Institutional Trust Company N.A. raised its stake in shares of Cerus Corp. by 0.6% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 2,559,771 shares of the company’s stock worth $15,179,000 after buying an additional 15,881 shares in the last quarter. Hood River Capital Management LLC raised its stake in shares of Cerus Corp. by 188.7% in the second quarter. Hood River Capital Management LLC now owns 1,888,557 shares of the company’s stock worth $11,785,000 after buying an additional 1,234,296 shares in the last quarter. Finally, State Street Corp raised its stake in shares of Cerus Corp. by 7.1% in the first quarter. State Street Corp now owns 1,520,015 shares of the company’s stock worth $9,015,000 after buying an additional 100,590 shares in the last quarter.
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
To view FBR & Co’s full report, visit FBR & Co’s official website.
Receive News & Ratings for Cerus Corp. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Cerus Corp. and related companies with MarketBeat.com’s FREE daily email newsletter.